Scientific experiments with the herpesvirus such as the one that causes Marek's disease in poultry have confirmed the highly controversial theory that some vaccines could allow more-virulent versions of a virus to survive, putting unvaccinated individuals at greater risk of severe illness.
"The challenge for the future is to identify other vaccines that also might allow more-virulent versions of a virus to survive and possibly to become even more harmful," said Andrew Read, an author of the paper published in the journal PLoS Biology, from the Penn State University.
These vaccines are a type that is "perfect" because they are designed to mimic the perfect immunity that humans naturally develop after having survived one of these diseases.
"Our research demonstrates that another vaccine type allows extremely virulent forms of a virus to survive - like the one for Marek's disease in poultry, against which the poultry industry is heavily reliant on vaccination for disease control," said Venugopal Nair, who led the research team in the UK where the experimental work was carried out.
Less-than-perfect vaccines create a 'leaky' barrier against the virus, so vaccinated individuals sometimes do get sick, but typically with less-virulent symptoms.
Because the vaccinated individuals survive long enough to transmit the virus to others, the virus also is able to survive and to spread throughout a population.
"In our tests of the leaky Marek's-disease virus in groups of vaccinated and unvaccinated chickens, the unvaccinated died while those that were vaccinated survived and transmitted the virus to other birds left in contact with them," Nair said.
The World Health Organisation recently reported laboratory-confirmed cases in China of human infection with the avian influenza virus, researchers said.
"We humans never have experienced any contagious disease that kills as many unvaccinated hosts as these poultry viruses can, but we now are entering an era when we are starting to develop next-generation vaccines that are leaky because they are for diseases that do not do a good job of producing strong natural immunity - diseases like HIV and malaria," Read added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
